BioCryst Pharmaceuticals Inc - Asset Resilience Ratio
BioCryst Pharmaceuticals Inc (BCRX) has an Asset Resilience Ratio of 14.37% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how BioCryst Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check BCRX strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down BioCryst Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BioCryst Pharmaceuticals Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $66.81 Million | 14.37% |
| Total Liquid Assets | $66.81 Million | 14.37% |
Asset Resilience Insights
- Moderate Liquidity: BioCryst Pharmaceuticals Inc has 14.37% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
BioCryst Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare BioCryst Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Alkem Laboratories Limited
NSE:ALKEM |
Drug Manufacturers - Specialty & Generic | 31.91% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Alkermes plc
F:8AK |
Drug Manufacturers - Specialty & Generic | 3.76% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
Annual Asset Resilience Ratio for BioCryst Pharmaceuticals Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for BioCryst Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.98% | $185.01 Million | $514.16 Million | -8.09pp |
| 2024-12-31 | 44.07% | $216.14 Million | $490.42 Million | -9.77pp |
| 2023-12-31 | 53.84% | $278.34 Million | $516.96 Million | +32.11pp |
| 2022-12-31 | 21.74% | $119.54 Million | $550.00 Million | +21.19pp |
| 2021-12-31 | 0.55% | $3.21 Million | $588.15 Million | -7.89pp |
| 2020-12-31 | 8.44% | $28.24 Million | $334.71 Million | -4.15pp |
| 2019-12-31 | 12.58% | $22.05 Million | $175.28 Million | -40.36pp |
| 2018-12-31 | 52.94% | $77.74 Million | $146.84 Million | +16.97pp |
| 2017-12-31 | 35.97% | $64.11 Million | $178.26 Million | -0.26pp |
| 2016-12-31 | 36.22% | $32.55 Million | $89.85 Million | +18.03pp |
| 2015-12-31 | 18.20% | $22.66 Million | $124.56 Million | +4.88pp |
| 2014-12-31 | 13.32% | $18.23 Million | $136.87 Million | -21.25pp |
| 2013-12-31 | 34.57% | $16.89 Million | $48.87 Million | +8.96pp |
| 2012-12-31 | 25.61% | $14.71 Million | $57.44 Million | -5.14pp |
| 2011-12-31 | 30.74% | $25.27 Million | $82.21 Million | -5.73pp |
| 2010-12-31 | 36.47% | $40.32 Million | $110.57 Million | +16.89pp |
| 2009-12-31 | 19.58% | $27.84 Million | $142.19 Million | -26.69pp |
| 2008-12-31 | 46.27% | $39.19 Million | $84.69 Million | +32.58pp |
| 2007-12-31 | 13.69% | $19.54 Million | $142.72 Million | -34.55pp |
| 2006-12-31 | 48.24% | $33.04 Million | $68.49 Million | +26.98pp |
| 2005-12-31 | 21.26% | $21.10 Million | $99.25 Million | -22.89pp |
| 2004-12-31 | 44.15% | $14.33 Million | $32.47 Million | +17.28pp |
| 2003-12-31 | 26.87% | $8.09 Million | $30.10 Million | +1.15pp |
| 2002-12-31 | 25.72% | $10.62 Million | $41.30 Million | +3.52pp |
| 2001-12-31 | 22.20% | $13.12 Million | $59.10 Million | -0.64pp |
| 2000-12-31 | 22.84% | $16.18 Million | $70.83 Million | +3.09pp |
| 1999-12-31 | 19.75% | $14.50 Million | $73.40 Million | -- |
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to… Read more